Union Bancaire Privee Trims Stake in Eli Lilly

Hedge fund reduces holdings in pharmaceutical giant by 3.7%

Mar. 21, 2026 at 11:44am

Got story updates? Submit your updates here. ›

Union Bancaire Privee UBP SA, a Swiss private banking group, has trimmed its stake in Eli Lilly and Company by 3.7% in the fourth quarter, according to a recent SEC filing. The fund now owns 84,298 shares of the pharmaceutical company's stock, valued at $92.5 million.

Why it matters

Eli Lilly is a major player in the pharmaceutical industry, known for its innovative diabetes and obesity treatments. This move by Union Bancaire Privee, a prominent hedge fund, could signal a shift in investor sentiment around the company's stock and future prospects.

The details

According to the filing, Union Bancaire Privee sold 3,199 shares of Eli Lilly during the fourth quarter, reducing its total holdings to 84,298 shares. The fund's stake in Eli Lilly now makes up about 1.4% of its overall portfolio.

  • Union Bancaire Privee filed the report with the SEC in the fourth quarter of 2026.

The players

Union Bancaire Privee UBP SA

A Swiss private banking group that manages assets for high-net-worth individuals and institutional clients.

Eli Lilly and Company

A global pharmaceutical company known for its innovative diabetes and obesity treatments.

Got photos? Submit your photos here. ›

The takeaway

This move by Union Bancaire Privee, a prominent hedge fund, could signal a shift in investor sentiment around Eli Lilly's stock and future prospects. However, the company remains a major player in the pharmaceutical industry, and its pipeline of innovative treatments continues to be closely watched by investors.